eWellness Healthcare (EWLL) 10-Q 13 Aug 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Aug. 13, 2021
Cover [Abstract]
Entity Registrant Name	eWELLNESS HEALTHCARE Corp
Entity Central Index Key	0001550020
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,707,683,628
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash		$ 1,109
Prepaid expenses	5,000	3,235
Total current assets	5,000	4,344
Property & equipment, net	3,385	3,788
TOTAL ASSETS	8,385	8,132
CURRENT LIABILITIES
Cash overdraft	3,487
Accounts payable and accrued expenses	987,863	892,164
Accrued expenses - related party	294,024	292,762
Accrued compensation	200,000	200,000
Convertible debt, net of discount	1,354,882	1,354,882
Derivative liability	2,147,698	3,925,106
Total current liabilities	4,987,954	6,664,914
Total Liabilities	4,987,954	6,664,914
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, authorized, 20,000,000 shares, $.001 par value, 696,667 and 696,667 hares issued and outstanding, respectively	697	697
Common stock, authorized 20,000,000,000 shares, $.001 par value, 16,864,183,627 and 16,862,481,961 issued and outstanding, respectively	16,864,184	16,862,482
Shares to be issued	195	263
Additional paid in capital	16,096,833	16,097,866
Accumulated deficit	(37,941,478)	(39,618,090)
Total Stockholders' Deficit	(4,979,569)	(6,656,782)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 8,385	$ 8,132

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	696,667	696,667
Preferred stock, shares outstanding	696,667	696,667
Common stock, shares authorized	20,000,000,000	20,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	16,864,183,627	16,862,481,961
Common stock, shares outstanding	16,864,183,627	16,862,481,961

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
REVENUE
Revenue		$ 14,375
Cost of revenue
Net Revenue		14,375
OPERATING EXPENSES
Executive compensation		187,000
General and administrative	23,167	346,690
Professional fees	13,820	467,418
Total Operating Expenses	36,987	1,001,108
Loss from Operations	(36,987)	(986,733)
OTHER INCOME (EXPENSE)
Interest income		1
Gain (loss) on derivative liability	1,777,408	(1,982,907)
Interest expense	(63,809)	(558,960)
Net Income (Loss) before Income Taxes	1,676,612	(3,528,599)
Income tax expense
Net Income (Loss)	$ 1,676,612	$ (3,528,599)
Basic and diluted income (loss) per common shares	$ 0	$ (0.02)
Weighted average shares outstanding	16,863,518,920	148,421,146

Reconciliation of Stockholders'

Reconciliation of Stockholders' Deficit (Unaudited) - USD ($)	Preferred Shares [Member]	Common Shares [Member]	Shares to be Issued [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2019	$ 250	$ 12,752	$ 150	$ 23,942,830	$ (30,862,019)	$ (6,906,037)
Balance, shares at Dec. 31, 2019	250,000	12,752,084
Contributed services				54,000		54,000
Shares issued to officers, directors and consultants	125			374,875		375,000
Shares issued to officers, directors and consultants, shares	125,000
Shares issued for debt conversion		$ 1,416,791		(634,247)		782,544
Shares issued for debt conversion, shares		1,416,790,494
Shares issued for services		$ 415	$ (150)	$ 392		$ 657
Shares issued for services, shares		415,000
Shares issued for rounding - 50:1 split		48		(48)
Shares issued for rounding - 50:1 split, shares		47,876
Derivative liability				$ 2,548,023		$ 2,548,023
Net loss					(3,528,599)	(3,528,599)
Balance at Mar. 31, 2020	$ 375	$ 1,430,006		26,285,825	(34,390,618)	(6,674,412)
Balance, shares at Mar. 31, 2020	375,000	1,430,005,454
Balance at Dec. 31, 2020	$ 697	$ 16,862,482	263	16,097,866	(39,618,090)	(6,656,782)
Balance, shares at Dec. 31, 2020	696,667	16,862,481,961
Shares issued for services		$ 1,702	(68)	(1,033)		601
Shares issued for services, shares		1,701,666
Net loss					1,676,612	1,676,612
Balance at Mar. 31, 2021	$ 697	$ 16,864,184	$ 195	$ 16,096,833	$ (37,941,478)	$ (4,979,569)
Balance, shares at Mar. 31, 2021	696,667	16,864,183,627

Reconciliation of Stockholder_2

Reconciliation of Stockholders' Deficit (Parenthetical)	Dec. 16, 2019	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Reverse stock split, description	1:50 reverse split	50:1 split

Consolidated Condensed Statem_2

Consolidated Condensed Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net income (loss)	$ 1,676,612	$ (3,528,599)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	402	2,079
Contributed services		54,000
Shares issued to officers, directors and consultants		186,250
Shares issued for consulting services	601	657
Discontinued adjustment
Shares issued for financing costs		73,750
Amortization of debt discount and prepaids	3,235	611,211
(Gain) loss on derivative liability	(1,777,408)	1,982,907
Changes in operating assets and liabilities
Prepaid expense	(5,000)	(21,888)
Accounts receivable		(14,375)
Overdraft cash	3,487
Accounts payable and accrued expenses	95,700	217,068
Accounts payable - related party		83,990
Accrued expenses - related party	1,262	18,402
Accrued compensation		60,501
Net cash used in operating activities	(1,109)	(274,047)
Cash flows from investing activities
Purchase of equipment
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issuance of convertible debt		52,800
Original issue discount and debt issuance costs		(7,800)
Net cash provided by financing activities		45,000
Net decrease in cash	(1,109)	(229,047)
Cash, beginning of period	1,109	240,722
Cash, end of period		11,675
Cash paid for:
Taxes
Interest Expense
Non cash items:
Derivative liability and debt discount issued with new notes		45,000
Shares issued for debt conversion		$ 782,544

The Company

The Company	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1. The Company The Company and Nature of Business eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated minimal revenues to date. eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a 15% ownership in Bistromatics. This agreement eliminated all past due professional fees of approximately $783,000. The transfer of rights was completed on December 31, 2020. During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and Management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company has engaged in negotiations with a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”), for a potential business combination. In connection with such negotiations, the Company’s Board of Directors on March 8, 2021, approved the organization of EWLL Acquisition Corp. under the laws of Nevada as a new wholly owned subsidiary of the Company (“EWLL Acquisition”). The purpose of the formation of EWLL Acquisition was in contemplation of its merger with and into AMHP which would be the surviving entity and become a wholly owned subsidiary of the Company. Pursuant to the Company’s intentions referenced above, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition and AMHP pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company, subject to filing of Articles of Merger with the State of Nevada. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist. On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2021. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020. The information regarding common stock shares, options and warrants throughout this document have been adjusted to reflect the 1:50 reverse split authorized by the Board of Directors on December 16, 2019 and further approved by FINRA on February 12, 2020. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments. Going Concern For the three months ended March 31, 2021, the Company had no revenue. The Company has an accumulated loss of $37,941,478 and a working capital deficit of $4,982,954. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. Fair Value of Financial Instruments As of March 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 2,147,698 $ - $ - $ 2,147,698 Total Liabilities measured at fair value $ 2,147,698 $ - $ - $ 2,147,698 As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 3,925,106 $ - $ - $ 3,925,106 Total Liabilities measured at fair value $ 3,925,106 $ - $ - $ 3,925,106 Revenue Recognition The Company recognizes revenue per ASC 606. Revenue is recognized when the services have been completed. Reclassifications Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 3. Related Party Transactions Throughout the three months ended March 31, 2021, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of March 31, 2021 and December 31, 2020 were $12,917 and $11,655, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $221,107 and $221,1070 as of March 31, 2021 and December 31, 2020, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $200,000 and $200,000 as of March 31, 2021 and December 31, 2020, respectively.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 4. Convertible Notes Payable During the three months ended March 31, 2021, there were no new convertible notes executed. During the three months ended March 31, 2021, the Company accrued interest payable of $63,808 on previously executed convertible notes payable. Year Ended December 31, 2020 In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. As of December 31, 2020, this note was fully converted and during the year ended December 31, 2020 the Company accrued interest of $2,880. During the year ended December 31, 2020, the Company accrued interest of $330,871 for the 2019 convertible notes that were still outstanding throughout the year.

Equity Transactions

Equity Transactions	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Equity Transactions	Note 5. Equity Transactions Preferred Stock The total number of shares of preferred stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $0.001 per share. During the year ended December 31, 2019, the Company authorized the issuance of 1,000,000 shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $3,000,000 and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two independent directors resigned and three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. As part of the Settlement and Compromise agreements signed by current officers, director and consultant on February 26, 2021, with effective date October 1, 2020, the shares issued became fully vested at the year ended December 31, 2020. In April 2020, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series D Preferred Stock in which the Board authorized a new series of Preferred Stock to be designated as Series D. The Board authorized two hundred thousand (200,000) shares to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock. The Series D Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation ; (ii) on parity with all equity securities issued by the Corporation with terms specifically providing that the Series B Preferred ranks on parity, except with respect to voting rights on which the Series B Preferred ranks junior to the Series D Preferred and except with respect to rights to the payment of dividends and the distribution of assets upon any liquidation, dissolution or winding up of the Corporation, which the Series B Preferred ranks senior to the Series D Preferred; and (iii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others in) existing subsidiaries of the Corporation. The term “equity securities” shall not include convertible debt securities The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time. As of the period ended March 31, 2021, there were no Series B or D issued and outstanding. Common Stock On February 12, 2020, FINRA approved a 1:50 reverse split of the Company’s common stock. As noted throughout this document, all common shares are stated as if the 1:50 reverse split had been completed as of the beginning of the year ended December 31, 2020. Following the approval, the Company’s stock began trading under the symbol “EWLLD”. Due to rounding issues for the reverse split, the Company issued 47,876 additional shares of common stock. On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (1,900,000,000) shares of Common Stock to twenty billion (20,000,000,000) shares of Common Stock Three Months Ended March 31, 2021 During the three months ended March 31, 2021, the Company issued 1,701,666 shares of common stock for consultant services valued at $601. Three Months Ended March 31, 2020 During the three months ended March 31, 2020, the Company issued a total of 1,416,790,494 shares of common stock per debt conversion of various convertible notes (see Note 4). The total of the debt conversion was for $643,998 of principal, $64,796 of accrued interest and $73,750 of financing costs. During the three months ended March 31, 2020, the Company issued 355,000 shares of common stock for consultant services valued at $465. During the three months ended March 31, 2020, the Company issued 60,000 shares of common stock for advisory services valued at $192. Stock Options The following is a summary of the status of all Company’s stock options as of March 31, 2021 and changes during the three months ended on that date: Weighted Number of Stock Average Exercise Remaining Intrinsic Options Price Life (yrs) Value Outstanding on December 31, 2020 27,000 $ 40.00 .14 $ - Granted - - Exercised - - Cancelled (27,000 ) - Outstanding on March 31, 2021 - - - $ - Options exercisable on March 31, 2021 - $ - - $ - Warrants The following is a summary of the status of the Company’s warrants as of March 31, 2021 and changes during the three months ended on that date: Weighted Number of Average Exercise Remaining Intrinsic Warrants Price Life (yrs.) Value Outstanding on December 31, 2020 26,015 $ 12.50 1.2 $ - Granted - - - - Exercised - - - - Cancelled (26,015 ) - - - Outstanding on March 31, 2021 - $ - - $ - Warrants exercisable on March 31, 2021 - $ - - $ -

Commitments, Contingencies

Commitments, Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies	Note 6. Commitments, Contingencies The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

Derivative Valuation

Derivative Valuation	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Valuation	Note 7. Derivative Valuation The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. Therefore, these have been characterized as derivative instruments. The Company records the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. The Company records the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings. The debt discount is amortized over the life of the note and recognized as interest expense. For the three months ended March 31, 2021 and 2020, the Company amortized the debt discount of $0 and $465,919, respectively. During the three months ended March 31, 2021, the Company had the following activity in the derivative liability account: Notes Derivative liability at December 31, 2020 $ 3,925,106 Change in fair value (1,777,408 ) Derivative liability at March 31, 2021 $ 2,147,698 For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows: Stock price at valuation date $ .0013 Exercise price of warrants $ 12.50 Risk free interest rate .01 % Stock volatility factor 241.82 % Years to Maturity .08 Expected dividend yield None

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 8. Subsequent Events On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. On May 12, 2021, the Board of Directors authorized 1,000,000 shares of Series C Convertible Preferred Stock, 200,000 shares of Series D Voting Preferred Stock and 2,500,000 shares of Series E Convertible Preferred Stock each series having a par value of $.0001. From Apri1 1 until the filing of this report, the Company issued 300,000 shares of common stock for consulting services for a value of $45. From April 1 until the filing of this report, the Company issued 920,000 shares of Series C Convertible Preferred shares, 200,000 shares of Series D Voting Preferred Shares and 1,630,000 shares of Series E Convertible Preferred shares. From April 1 until the filing of this report, the Company issued 843,200,000 shares of common stock for the conversion of 84,320 shares of Series E Convertible Preferred shares.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2021. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020. The information regarding common stock shares, options and warrants throughout this document have been adjusted to reflect the 1:50 reverse split authorized by the Board of Directors on December 16, 2019 and further approved by FINRA on February 12, 2020.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.
Going Concern	Going Concern For the three months ended March 31, 2021, the Company had no revenue. The Company has an accumulated loss of $37,941,478 and a working capital deficit of $4,982,954. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As of March 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 2,147,698 $ - $ - $ 2,147,698 Total Liabilities measured at fair value $ 2,147,698 $ - $ - $ 2,147,698 As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 3,925,106 $ - $ - $ 3,925,106 Total Liabilities measured at fair value $ 3,925,106 $ - $ - $ 3,925,106
Revenue Recognition	Revenue Recognition The Company recognizes revenue per ASC 606. Revenue is recognized when the services have been completed.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Assets and Liabilities Fair Value on Recurring Basis	As of March 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 2,147,698 $ - $ - $ 2,147,698 Total Liabilities measured at fair value $ 2,147,698 $ - $ - $ 2,147,698 As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 3,925,106 $ - $ - $ 3,925,106 Total Liabilities measured at fair value $ 3,925,106 $ - $ - $ 3,925,106

Equity Transactions (Tables)

Equity Transactions (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Summary of Stock Options Activity	The following is a summary of the status of all Company’s stock options as of March 31, 2021 and changes during the three months ended on that date: Weighted Number of Stock Average Exercise Remaining Intrinsic Options Price Life (yrs) Value Outstanding on December 31, 2020 27,000 $ 40.00 .14 $ - Granted - - Exercised - - Cancelled (27,000 ) - Outstanding on March 31, 2021 - - - $ - Options exercisable on March 31, 2021 - $ - - $ -
Summary of Warrants Activity	The following is a summary of the status of the Company’s warrants as of March 31, 2021 and changes during the nine months ended on that date: Weighted Number of Average Exercise Remaining Intrinsic Warrants Price Life (yrs.) Value Outstanding on December 31, 2020 26,015 $ 12.50 1.2 $ - Granted - - - - Exercised - - - - Cancelled (26,015 ) - - - Outstanding on March 31, 2021 - $ - - $ - Warrants exercisable on March 31, 2021 - $ - - $ -

Derivative Valuation (Tables)

Derivative Valuation (Tables)	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liability	During the three months ended March 31, 2021, the Company had the following activity in the derivative liability account: Notes Derivative liability at December 31, 2020 $ 3,925,106 Change in fair value (1,777,408 ) Derivative liability at March 31, 2021 $ 2,147,698
Schedule of Assumptions Used Black Scholes Valuation of Derivative	For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows: Stock price at valuation date $ .0013 Exercise price of warrants $ 12.50 Risk free interest rate .01 % Stock volatility factor 241.82 % Years to Maturity .08 Expected dividend yield None

The Company (Details Narrative)

The Company (Details Narrative) - USD ($)	Apr. 19, 2021	Sep. 15, 2020	Mar. 31, 2021	Mar. 31, 2020
Professional fees			$ 13,820	$ 467,418
Bistromatics Inc. [Member] | Services Agreement [Member]
Ownership percentage		15.00%
Professional fees		$ 783,000
American Health Protection Corp. [Member] | Subsequent Event [Member]
Common stock conversion basis	(i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”).

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 16, 2019	Mar. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Reverse stock split, description	1:50 reverse split	50:1 split
Accumulated deficit		$ (37,941,478)	$ (39,618,090)
Working capital deficit		$ 4,982,954

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Derivative Liability	$ 2,147,698	$ 3,925,106
Total Liabilities measured at fair value	2,147,698	3,925,106
Level 1 [Member]
Derivative Liability
Total Liabilities measured at fair value
Level 2 [Member]
Derivative Liability
Total Liabilities measured at fair value
Level 3 [Member]
Derivative Liability	2,147,698	3,925,106
Total Liabilities measured at fair value	$ 2,147,698	$ 3,925,106

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Accrued directors' fees	$ 221,107	$ 2,211,070
Accrued executive compensation	200,000	200,000
Officers and Directors [Member]
Due to related party	$ 12,917	$ 11,655

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	1 Months Ended
	Mar. 31, 2020USD ($)Integer	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Convertible Notes Payable [Member]
Accrued interest		$ 63,808
12% Convertible Promissory Note [Member]
Accrued interest			$ 2,880
Debt interest stated rate	12.00%
Debt face amount	$ 52,800
Debt maturity date	Jan. 15, 2021
Original issue discount	$ 4,800
Transaction costs	$ 3,000
Convertible debt percentage	70.00%
Number of trading days | Integer	10
2019 Convetible Notes [Member]
Accrued interest			$ 330,871

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	Feb. 12, 2020	Dec. 16, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Apr. 30, 2020	Feb. 14, 2020
Preferred stock, shares authorized			20,000,000			20,000,000
Preferred stock, par value			$ 0.001			$ 0.001
Deferred compensation			$ 3,000,000
Common stock, par value			$ 0.001			$ 0.001	$ 0.001
Reverse stock split, description		1:50 reverse split	50:1 split
Common stock, shares authorized			20,000,000,000			20,000,000,000
Shares issued during period for services, value			$ 601	$ 657
Advisory Services Agreement [Member]
Number of shares issued, new issues				60,000
Stock issued during the period, value				$ 192
Convertible Notes [Member]
Shares issued for debt conversion, shares				1,416,790,494
Principal amount				$ 643,998
Accrued interest				64,796
Financing costs				$ 73,750
Preferred Shares [Member]
Conversion of stock, shares			40
Conversion of stock, description			The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance.
Shares issued during period for services, shares
Shares issued during period for services, value
Shares issued for debt conversion, shares
Common Shares [Member]
Common stock, shares authorized			20,000,000,000					1,900,000,000
Shares issued during period for services, shares			1,701,666	415,000
Shares issued during period for services, value			$ 1,702	$ 415
Shares issued for debt conversion, shares				1,416,790,494
Officers, Directors and Consultants [Member]
Preferred stock, shares authorized					1,000,000
Board of Directors [Member] | Series D Preferred Stock [Member]
Preferred stock, shares authorized							200,000
Board of Directors [Member] | Common Shares [Member]
Reverse stock split, description	1:50 reverse split				1:50 reverse split
Number of shares issued, new issues					47,876
Consultant [Member]
Number of shares issued, new issues				355,000
Shares issued during period for services, shares			1,701,666
Shares issued during period for services, value			$ 601
Stock issued during the period, value				$ 465

Equity Transactions - Summary o

Equity Transactions - Summary of Stock Options Activity (Details)	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Equity [Abstract]
Number of Stock Options Outstanding, Beginning Balance | shares	27,000
Number of Stock Options Outstanding, Granted | shares
Number of Stock Options Outstanding, Exercised | shares
Number of Stock Options Outstanding, Expired/ cancelled | shares	(27,000)
Number of Stock Options Outstanding, Ending Balance | shares
Number of Stock Options exercisable, Ending Balance | shares
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 40
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares
Weighted Average Exercise Price Options exercisable, Ending Balance | $ / shares
Remaining Life (yrs) Outstanding, Beginning Balance	1 month 20 days
Intrinsic Value Outstanding, Beginning Balance | $
Intrinsic Value Outstanding, Ending Balance | $
Intrinsic Value Options exercisable, Ending Balance | $

Equity Transactions - Summary_2

Equity Transactions - Summary of Warrants Activity (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Equity [Abstract]
Number of Warrants, Outstanding, Beginning Balance | shares	26,015
Number of Warrants, Granted | shares
Number of Warrants, Exercised | shares
Number of Warrants, Cancelled | shares	(26,015)
Number of Warrants, Outstanding, Ending Balance | shares
Number of Warrants, exercisable, Ending balance | shares
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance	$ 12.50
Weighted Average Exercise Price, Warrants Granted
Weighted Average Exercise Price, Warrants Exercised
Weighted Average Exercise Price, Warrants Cancelled
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance
Weighted Average Exercise Price Exercisable, Ending Balance
Remaining Life (yrs.) Warrants Outstanding, Beginning Balance	1 year 2 months 12 days
Intrinsic Value, Warrants Outstanding, Beginning Balance
Intrinsic Value, Warrants Outstanding, Ending Balance

Derivative Valuation (Details N

Derivative Valuation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Amortized of debt discount	$ 3,235	$ 611,211
Derivative Liability [Member]
Amortized of debt discount	$ 0	$ 465,919

Derivative Valuation - Schedule

Derivative Valuation - Schedule of Derivative Liability (Details) - Notes [Member]	3 Months Ended
	Mar. 31, 2021USD ($)
Derivative liability, beginning balance	$ 3,925,106
Change in fair value	(1,777,408)
Derivative liability, ending balance	$ 2,147,698

Derivative Valuation - Schedu_2

Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) - Derivative Liability [Member]	3 Months Ended
	Mar. 31, 2021$ / shares
Stock price at valuation date	$ 0.0013
Exercise price of warrants	$ 12.50
Derivative liability, term	29 days
Risk Free Interest Rate [Member]
Derivative liability, fair value measurement input, percentage	0.01
Stock Volatility Factor [Member]
Derivative liability, fair value measurement input, percentage	241.82
Expected Dividend Yield [Member]
Derivative liability, fair value measurement input, percentage	0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Apr. 19, 2021	Mar. 31, 2021	Mar. 31, 2020	Aug. 13, 2021	May 12, 2021	Dec. 31, 2020
Preferred stock, par value		$ 0.001				$ 0.001
Preferred stock, shares authorized		20,000,000				20,000,000
Shares issued during period for services, value		$ 601	$ 657
Subsequent Event [Member]
Preferred stock, par value					$ 0.0001
Number of shares issued, new issues				843,200,000
Subsequent Event [Member] | Consulting Services [Member]
Shares issued during period for services, shares				300,000
Shares issued during period for services, value				$ 45
Subsequent Event [Member] | Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized					1,000,000
Number of shares issued, new issues				920,000
Subsequent Event [Member] | Series D Voting Preferred Stock [Member]
Preferred stock, shares authorized					200,000
Number of shares issued, new issues				200,000
Subsequent Event [Member] | Series E Convertible Preferred Stock [Member]
Preferred stock, shares authorized					2,500,000
Number of shares issued, new issues				1,630,000
Shares issued for debt conversion, shares				84,320
Subsequent Event [Member] | American Health Protection Corp. [Member]
Common stock conversion basis	(i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”).